twitter
en POLSKI
eISSN: 2719-3209
ISSN: 0023-2157
Klinika Oczna / Acta Ophthalmologica Polonica
Current issue Archive Videos Articles in press About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2/2004
vol. 106
 
Share:
Share:
abstract:
Preface

The influence of rilmenidine on intraocular pressure in rabbits. Interaction with efaroxan and rauwolscine

Marta Misiuk-Hojło
1
,
Marek Szaliński
1
,
Anna Merwid-Ląd
2
,
Małgorzata Trocha
2
,
Małgorzata Pieśniewska
2

  1. Z Katedry i Kliniki Okulistyki Akademii Medycznej we Wrocławiu
  2. Z Katedry i Zakładu Farmakologii Akademii Medycznej we Wrocławiu
Online publish date: 2004/02/21
View full text Get citation
 
Purpose
Glaucoma is the main cause of blindness in the developed countries. Its progress can be diminished by decreasing intraocular pressure (IOP) using pharmacological or surgical treatment. Antiglaucoma agents, α2 – adrenergic's receptor agonists have been known for several years as IOP lowering. Due to the fact that the majority of them turned out to be imidazoline receptor agonists, it is worth checking if selective imidazoline receptor (I1) agonists alter IOP. Preliminary animal experiments show that they lower IOP. In our study we examined the influence of rilmenidine, a potent I1 receptor agonist, on IOP in rabbits. Furthermore, we tried to find out whether I1 and α2 receptor antagonists (efaroxan and rauwolscine) counteract the pharmacological effect of rilmenidine.

Material and methods
The study was conducted on adult male White New Zealand rabbits. All the substances were administered topically, and IOP was measured by applanation tonometry after topical anaesthesia before and 1, 3 and 5 hours after drug instillation.

Results
Rilmenidine showed the lowering effect on IOP at the concentration of 0,4%. Efaroxan and rauwolscine partly inhibited rilmenidine effect.

Conclusions
Rilmenidine is a potential antiglaucoma agent, though further studies are necessary

keywords:

Intraocular pressure, rilmenidine, efaroxan, rauwolscine, glaucoma, animal study

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.